Suven gets patents from New Zealand, Eurasia

24 Dec 2010 Evaluate

Drug firm Suven Life Sciences has received four product patents for its new chemical entities (NCEs), used in treating disorders like Alzheimer's disease, Parkinson and Schizophrenia. The company has received two patents each from New Zealand and Eurasia, which are valid until 2022 and 2025 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. The molecules in the CNS arena that are being developed for cognitive disorders have an estimated $30 billion market potential globally. Products of these inventions may be out licensed at various phases of clinical development like phase I or phase II.

Suven Life Sciences Share Price

128.85 -2.40 (-1.83%)
04-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1709.40
Dr. Reddys Lab 1109.75
Cipla 1415.55
Lupin 1971.10
Zydus Lifesciences 866.65
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...